Earlier this week, the Information Technology and Innovation Foundation (ITIF) released a report that offers a rebuttal to nine claims it identifies with the “anti-IP progressive orthodoxy.”
In its current form, globalization has exacerbated inequalities. Globalization 2.0 must address the political ramifications and power imbalance of these cleavages, particularly in trade, data and technology, finance, tax, and climate change policies.
Additional 230 Million Indians Fell Below Poverty Line Due to the Pandemic: Study
The study, State of Working India 2021 â One year of Covid-19 , by Azim Premji University has touched upon several aspects pertaining to the state of the Indian economy.
File photo of a volunteer distributing food to migrant workers travelling home at a Kanyakumari railway station. Photo: PTI
Health18 hours ago
New Delhi: At a time when the second wave of the COVID-19 pandemic is ravaging India, a report prepared by the Centre for Sustainable Employment at Azim Premji University (APU) has highlighted how employment and income had not recovered to pre-pandemic levels even in late 2020 and the latest surge in cases would only add to the devastation and distress.
To the Editor:
(Op-Ed, nytimes.com, Dec. 7):
Of all of the ways to improve access to critical medication or vaccines, elimination of intellectual property rights is one of the worst. Our intellectual property system is designed to reward research and development innovation.
Tampering with that sends a chilling signal about the rewards of corporate funding of the development and manufacture of new drugs, and tears down a system that has allowed the U.S. government to realize an enormous return on its investment into biomedical research.
The government has many other options to achieve the important public policy goal of providing broad access to vaccines. It can encourage and reward out-licensing and technology transfer, negotiate preferential pricing or simply provide volume purchasing guarantees options that would not have the unfortunate effect of discouraging pharmaceutical innovation. We need effective vaccines not just for this emergency, but for the next one as well.
Share this article As the coronavirus pandemic tears through rural and urban America, healthcare workers and others at-risk of catching the disease are receiving life-saving vaccines now. Meanwhile, in a new development, opposing views of vaccine policy are front and center in the U.S. paper of record. First, we turn to the pharmaceutical industry, a powerhouse interest. Thomas Cueni is the director-general of the International Federation of Pharmaceutical Manufacturers and Associations. In a recent New York Times column, he opposed halting patents, or intellectual property rights, to accelerate companies’ distribution of coronavirus vaccines. (Uncle Sam is the authority that grants patents.)